Search Results
67 items found for "juan jose fung"
- Domain Therapeutics Raises $42m Series A Financing
$42m (€39m) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund
- Chemokine receptor-targeted drug discovery: progress and challenges
antibody mogamulizumab has also been approved in Japan and by the FDA for the treatment of mycosis fungoides molecular redundancy, pointing out that, in some cases, inappropriate target selection and insufficient dosing
- The sixth transmembrane region of a pheromone G-protein coupled receptor, Map3, is implicated in ...
In ascomycete fungi including yeasts, mating between cells of opposite mating type depends on the molecular
- 📰 GPCR Weekly News, October 9 to 15, 2023
Modes of Action A non-pheromone GPCR is essential for meiosis and ascosporogenesis in the wheat scab fungus
- 4GPCRnet - International Symposium
Four of the biggest European networks on GPCR research (COST Actions Adher’n Rise and ERNEST plus DFG-funded
- Nanobodies: New Dimensions in GPCR Signaling Research
., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D. M., Thian, F.
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
US $900,000) of additional research funding.
- 📰 GPCR Weekly News
Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders Inversago Pharma Doses
- 📰 GPCR Weekly News, August 7 to 13, 2023
Financial Results And Provides Corporate Update Sosei Heptares and Cancer Research UK Announce the Dosing
- The Bile Acid Membrane Receptor TGR5 in Cancer: Friend or Foe?
TGR5 is widely distributed in the brain, lung, heart, liver, spleen, pancreas, kidney, stomach, jejunum
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
In 2016 the company was sold to Velocity fund partners and has been rebranded as InClinica.
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
subtype-selective ligands for dopamine receptors and adenosine receptors (He, Ben, Kuang, Wang & Kong, 2016; Kuang, Feng GPCR-related knowledge, AI can help identify patient-specific GPCR targets and optimize drug selection and dosing
- 📰 GPCR Weekly News, September 18 to 24, 2023
human islets AT2 receptor agonist LP2 restores respiratory function in a rat model of bleomycin-induced lung G protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung
- 📰 GPCR Weekly News, March 18 to 24, 2024
uncovering the natural mutations of L->Q, I->T, F->Y and Q->L, T->I and Y->F Industry News Sosei Heptares Doses
- 📰 GPCR Weekly News, June 5 to 11, 2023
EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular
- 📰 GPCR Weekly News, April 22 to 28, 2024
transmembrane proteome profiling in mental disease models Reviews, GPCRs, and more The nematode-trapping fungus prey pheromones via G protein-coupled receptors Structural and Molecular Insights into GPCR Function Fungal
- Regulator of G Protein Signaling 20 Correlates with Long Intergenic Non-Coding RNA (lincRNAs)...
to be an important factor for survival in four other cancers (clear renal cell carcinoma: p < 0.001, lung
- 📰 GPCR Weekly News, January 15 to 21, 2024
Receptor Gpr-1 Is Important for the Growth and Nutritional Metabolism of an Invasive Bark Beetle Symbiont Fungi
- 📰 GPCR Weekly News, September 11 to 17, 2023
receptor sensor GPCRs in Oncology and Immunology Phase 1/2 study of sorafenib added to cladribine, high-dose
- 📰 GPCR Weekly News, July 31 to August 6, 2023
and Immunology GPCRs and fibroblast heterogeneity in fibroblast-associated diseases Ultrasensitive dose-response neuropeptide transmission Nanowire Biosensors with Olfactory Proteins: Towards a genuine electronic nose
- 📰 GPCR Weekly News, May 29 to June 4, 2023
GPCRs in Oncology and Immunology A2aR on lung adenocarcinoma cells: A novel target for cancer therapy Components of TOR and MAP kinase signaling control chemotropism and pathogenicity in the fungal pathogen
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
structure and activation mechanisms of GPCRs, the biotech investment community has injected significant funding Twice-daily treatment with mOB-004 dose-dependently suppressed monocyte infiltration into the peritoneum cavity, achieving complete blockade at the highest dose level.
- 📰 GPCR Weekly News, July 3 to 9, 2023
Immunology Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung
- 📰 GPCR Weekly News, October 2 to 8, 2023
at symposium honoring Nobel Laureate Robert Lefkowitz Integral Molecular Secures Nearly $900K in NIH Funding
- 📰 GPCR Weekly News
team in Oxford, buying out a fledgling biotech for $255M+ Domain Therapeutics announces first patient dosed
- Targeting Intracellular Allosteric Sites in GPCRs
of adjustability in terms of pharmacological effects, allowing for the administration of substantial doses
- 📰 GPCR Weekly News, May 22 to 28, 2023
patients with WHIM syndrome Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung
- Overview of adhesion GPCRs self-activation
., Duan, Y., Yin, H., Xiong, Y., Zhang, A., Guo, C., Chen, Z., Huang, Z., & He, Y. (2022).